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ABSTRACT 
Cochrane Reviews summarise best evidence and should inform guidelines. We assessed the use of 
Cochrane Reviews in UK guidelines for paediatric respiratory disease. We found 21 guidelines which 
made 1025 recommendations, of which 96 could be informed by a Cochrane Review. In 38/96 
recommendations (40%), some or all of the relevant Cochrane Reviews were not cited.  We linked 
recommendations to 140 Cochrane Reviews. In 37/140 (26%) cases, the guideline recommendation 
did not fully agree with the Cochrane Review.  Guideline developers may fail to use Cochrane 
Reviews or may make recommendations which are not in line with best evidence.   
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INTRODUCTION 
 
Clinical practice guidelines support optimal decision making in medical care.  Guidelines should use 
the best available evidence (1). Systematic reviews use transparent criteria (such as GRADE) to 
evaluate the quality of evidence (2) and so systematic reviews (where available) should be the 
primary source of evidence in guidelines. The Cochrane Collaboration produces systematic reviews 
(‘Cochrane Reviews’) using a rigorous methodology. These are peer reviewed at the protocol and 
review stage, and are updated regularly (3). Previous work indicates that guidelines do not make full 
use of Cochrane Reviews (4, 5). This represents research wastage, and may lead to suboptimal 
medical care.    
 
Respiratory disease in children is common - 20% of children visiting the emergency department, with 
a medical problem, will have a respiratory illness (6).   However, the paediatric respiratory evidence 
base is limited. Nearly half of children with respiratory disease receive a medication which is off-
label or unlicensed (7). It is particularly important that guidelines for respiratory disease in children 
make the best use of this limited evidence. We examined the use of evidence from Cochrane 
Reviews in guidelines for respiratory disease in children.    
 
We aimed to understand the use of the best available evidence in the field of paediatric respiratory 
medicine.  We systematically examined the use of Cochrane Reviews in UK clinical guidelines for 
lower respiratory diseases in children and we examined the agreement between the guideline 
recommendations and the Cochrane Reviews. We investigated the association between guideline 
commissioning agency, the topic, the publication year and the use of alternate high quality evidence 
upon whether Cochrane Reviews were cited, and whether their conclusions were followed.  
 
METHODS 
We identified all the respiratory guidelines in the UK for lower respiratory tract disease for children 
via database and web searches.  We simultaneously identified all the Cochrane reviews relevant to 
paediatric respiratory medicine, via the Cochrane library.  For each guideline, we included all 
recommendations pertaining to an intervention for lower respiratory tract disease in children.  For 
each recommendation, we identified if there was a Cochrane review which could inform it, and 
which had been published at least one year prior to the guideline.  We mapped each guideline 
recommendation to relevant Cochrane reviews.   
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For each linked guideline recommendation – Cochrane review, we categorized the agreement 
between the guideline recommendation and the Cochrane review into one of four categories:  (i) 
totally, (ii) partially, (iii) not in agreement, or (iv) a strong guideline recommendation where the 
Cochrane review concluded that there was not enough evidence to draw a conclusion (see 
Supplementary information file 1 for definitions and examples).  Where guideline recommendations 
disagreed with the Cochrane review, we categorized the extent of the disagreement.  The protocol 
(including study eligibility criteria and statistical analysis plan) was produced in advance of the data 
collection, is available at the University of Nottingham ePrints server and as supplementary files 2 
and 3).  Detailed methods are provided in Supplementary Information. 
RESULTS 
Guidelines and Cochrane Reviews identified 
We included 21 guidelines and 236 Cochrane Reviews (see Figure 1). The 21 guidelines made 1025 
recommendations of which 555 were for treatment of lower respiratory disease in children. We 
identified relevant Cochrane Reviews for 96 (17.3%) of these 555 recommendations.  
Of the 96 recommendations that could use Cochrane Reviews, 28/96 (29%) did not use any, and 
10/96 (10%) did not use all the available Cochrane Reviews.  There were 140 instances where a 
Cochrane Review could be linked to at least one guideline recommendation.   Of these 103/140 
(74%) were in agreement, 13/140 (9%) were partially in agreement, 5/140 (4%) disagreed and 19 / 
140 (13%) were strong recommendations but the Cochrane Review did not draw a conclusion.  Few 
Cochrane Reviews in paediatric respiratory medicine are able draw a strong conclusion, 96/283 
(34%).    
We summarise these data in Figure 2.  An on-line interactive version of this figure allowing the 
reader to directly explore the data within a web browser is available at <insert link>, and can be 
downloaded directly from <inset link>.  
Further analysis is presented in the online supplement, including a sensitivity analysis of our 
judgements in categorizing agreement and an analysis investigating the impact of commissioning 
agency, guideline topic, guideline year and guideline use of alternate high quality evidence on the 
use of Cochrane reviews. 
 
DISCUSSION 
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We found that 38/96 (40%) of guideline recommendations did not use all the relevant Cochrane 
Reviews. The majority of guideline recommendations were in agreement with Cochrane Review 
recommendations. We present the data as an interactive figure allowing the reader to explore the 
links between Cochrane Reviews and guideline recommendations.   
Our results are broadly in keeping with studies in other fields such as smoking cessation and 
neonatal medicine which show that guidelines do not make the best use of Cochrane Reviews. Silagy 
et al (4) found four guidelines for smoking cessation (one from the UK). In the UK guideline 16/22 
recommendations could have cited a Cochrane Review but only 8 recommendations did so.  Brok et 
al (5)studied the agreement between guidelines and Cochrane Reviews for new-borns in Denmark.  
Compared to our study, they found similar discrepancies between Cochrane Reviews and guideline 
recommendations - 24% were not in agreement (of which 6% partially agreed, and 18% disagreed).    
Our study is comprehensive, used an a priori protocol, and categorizations were conducted 
independently by two investigators.  The study has limitations, including the subjectivity in decisions 
regarding agreement and disagreement.  We expand on this in supplementary file 2.   
Conclusion 
In spite of the work of the Cochrane collaboration, there are still many treatment decisions where 
there is no systematic review to inform guideline recommendations. However, we have shown that, 
even where a Cochrane Reviews exists, guideline developers may not make use of it or may make 
recommendations contrary to the findings of the review. This study demonstrates that only a 
minority of recommendations in clinical practice guidelines are based on the highest quality 
evidence.  A great deal of money, time and effort goes into creating and updating Cochrane Reviews.  
Not using such evidence in guidelines constitutes research waste.    
  7 
 
Figure 1.  Flow diagram of the selection of guidelines and Cochrane Reviews 
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<see attachment pdf for Figure 2> 
Figure 2.  Do Cochrane Reviews influence clinical practice guideline 
recommendations?  Evidence network diagram to show the links between Cochrane 
Reviews and Guideline recommendations.  Each individual guideline 
recommendation is represented by a purple node, and each Cochrane review by a 
green node.  A solid blue line connecting a guideline recommendation to a Cochrane 
recommendation indicates that the guideline cited the Cochrane Review, and the two 
are in agreement.  A broken line indicates that the guideline did not cite the 
Cochrane Review.  A brown line indicates that the Cochrane Review and guideline 
were not totally in agreement.  Panel A shows all the links.  Subsequent panels are 
sub-grouped by disease topic: B = asthma, C = cystic fibrosis, D = respiratory 
infections and E = respiratory aspects of critical care.  An interactive web based 
version of the evidence network diagram (which loads in all recent major browsers) 
is available at <insert hyperlink>, and allows the reader to explore the underlying 
data further.   
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